[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7649 Introduced in House (IH)]
<DOC>
117th CONGRESS
2d Session
H. R. 7649
To direct the Secretary of Health and Human Services to open a public
docket for the submission of public comments regarding factors that
should be taken into consideration when reviewing a proposed
modification to an approved risk evaluation and mitigation strategy,
and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 3, 2022
Mr. Joyce of Pennsylvania (for himself, Ms. Matsui, and Mr. Griffith)
introduced the following bill; which was referred to the Committee on
Energy and Commerce
_______________________________________________________________________
A BILL
To direct the Secretary of Health and Human Services to open a public
docket for the submission of public comments regarding factors that
should be taken into consideration when reviewing a proposed
modification to an approved risk evaluation and mitigation strategy,
and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. PUBLIC DOCKET ON PROPOSED MODIFICATIONS TO APPROVED
STRATEGIES.
(a) In General.--Not later than 90 days after the date of the
enactment of this Act, the Secretary of Health and Human Services shall
open a public docket for the submission of public comments regarding
factors that should be taken into consideration when a proposed
modification to an approved risk evaluation and mitigation strategy is
reviewed under section 505-1(h) of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 255-1(h)), including factors related to patient access
to the drug that is the subject of the strategy and provider
administration. The Secretary may close such public docket not earlier
than 90 days after such docket is opened.
(b) GAO Report.--Not later than December 31, 2026, the Comptroller
General of the United States shall submit to the Committee on Energy
and Commerce of the House of Representatives and the Committee on
Health, Education, Labor, and Pensions of the Senate a report on--
(1) the number of proposed modifications to an approved
risk evaluation and mitigation strategy the Secretary has
granted under section 505-1(h) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 255-1(h));
(2) any issues affecting patient access to the drug that is
the subject of the strategy or provider administration that
arose as a result of such modifications; and
(3) how such issues were resolved, as applicable.
<all>